Home » Healthcare » Breast Cancer Core Needle Biopsy Market
Breast Cancer Core Needle Biopsy Market By Technology (MRI-based Breast Biopsy, Ultrasound-based Breast Biopsy, Mammography-based Breast Biopsy, CT-based Breast Biopsy, Other Image-Based Breast Biopsy); By Application (Breast Lesion Diagnosis, Breast Cancer Confirmation, Calcification Sampling, Histopathology / Tissue Characterization); By End User (Hospitals, Diagnostic Imaging Centers, Ambulatory Surgical Centers, Specialty Breast Care Clinics, Research and Academic Institutes); By Region – Growth, Share, Opportunities & Competitive Analysis, 2025 – 2032
The global Breast Cancer Core Needle Biopsy Market size was estimated at USD 923.45 million in 2025 and is expected to reach USD 1,256.69 million by 2032, growing at a CAGR of 4.5% from 2025 to 2032. Growth is primarily driven by the steady rise in breast cancer screening and follow-up imaging that increases the need for tissue confirmation using minimally invasive biopsy procedures. Breast Cancer Core Needle Biopsy Market expansion is further supported by wider availability of image-guided biopsy workflows across hospitals and diagnostic imaging centers, enabling faster diagnosis and streamlined care pathways.
REPORT ATTRIBUTE
DETAILS
Historical Period
2020-2024
Base Year
2025
Forecast Period
2026-2032
Breast Cancer Core Needle Biopsy Market Size 2025
USD 923.45 million
Breast Cancer Core Needle Biopsy Market, CAGR
4.5%
Breast Cancer Core Needle Biopsy Market Size 2032
USD 1,256.69 million
Key Market Trends & Insights
Breast Cancer Core Needle Biopsy Market is projected to grow from USD 923.45 million (2025) to USD 1,256.69 million (2032) at a 4.5% CAGR (2025–2032).
Ultrasound-based Breast Biopsy accounted for the largest share of 42.3% in 2025, supported by real-time guidance and broad deployment across imaging settings.
Hospitals represented the leading end-user segment with 59.2% share in 2025, reflecting higher procedure volumes and integrated imaging-pathology workflows.
North America remained the leading region with 45.80% share in 2025, driven by strong screening penetration and advanced diagnostic infrastructure.
Asia Pacific (22.40%) and Europe (21.30%) together represented 43.70% of 2025 revenue, reflecting expanding diagnostics capacity and sustained screening-driven demand.
Segment Analysis
Breast Cancer Core Needle Biopsy Market demand is anchored in the need for accurate, minimally invasive tissue sampling to confirm malignancy, characterize lesions, and guide treatment decisions. The market benefits from improvements in imaging guidance, device ergonomics, and biopsy workflow standardization across clinical settings. Providers increasingly prioritize biopsy approaches that reduce procedure time, minimize repeat sampling, and generate sufficient tissue for histopathology and biomarker evaluation.
Breast Cancer Core Needle Biopsy Market segmentation reflects how clinicians select guidance modality and care setting based on lesion type, imaging visibility, and facility capability. Ultrasound-guided biopsy remains widely preferred when lesions are visible on ultrasound because the procedure supports real-time targeting and efficient patient throughput. Hospitals continue to account for the largest procedure volumes due to integrated imaging availability, complex referral pathways, and in-house pathology coordination.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
Ultrasound-based Breast Biopsy accounted for the largest share of 42.3% in 2025. Ultrasound guidance leads because the procedure supports real-time needle visualization and efficient workflow in routine lesion sampling. Ultrasound-guided pathways are also more widely available than MRI-guided workflows across diagnostic networks, supporting higher procedure volumes. Breast Cancer Core Needle Biopsy Market adoption for ultrasound guidance benefits from cost and infrastructure advantages that allow deployment across both large hospitals and mid-tier imaging centers.
By Application Insights
Breast Cancer Core Needle Biopsy Market application demand is primarily shaped by follow-up of suspicious imaging findings and the clinical need for tissue confirmation. Breast lesion diagnosis and breast cancer confirmation remain central because clinicians require histopathologic results to differentiate benign findings from malignancy and to support treatment planning. Calcification sampling continues to depend on image-guided workflows where stereotactic or mammography-based guidance is preferred in many cases. Histopathology and tissue characterization needs reinforce routine use of core needle biopsy to support receptor and biomarker assessment.
By End User Insights
Hospitals accounted for the largest share of 59.2% in 2025. Hospitals lead due to higher diagnostic volumes, established multidisciplinary breast programs, and access to multiple imaging guidance modalities for complex lesion workups. Hospitals also concentrate referrals from screening programs and specialty clinics, which supports sustained biopsy throughput. Breast Cancer Core Needle Biopsy Market utilization in hospitals is further strengthened by integrated pathology and oncology coordination that shortens diagnosis-to-treatment timelines.
Breast Cancer Core Needle Biopsy Market Drivers
Expansion of screening and diagnostic follow-up pathways
Breast Cancer Core Needle Biopsy Market growth is supported by increasing use of screening mammography and supplemental imaging that generates more follow-up investigations. More detected abnormalities and higher-risk patient monitoring increase the need for confirmatory tissue sampling. Core needle biopsy remains a preferred approach because the procedure is minimally invasive and delivers clinically actionable pathology. Breast Cancer Core Needle Biopsy Market demand rises as providers aim to reduce unnecessary surgeries and accelerate diagnosis-to-treatment workflows.
For instance, a multicenter U.S. study of 2,528,063 screening mammograms reported that digital breast tomosynthesis increased cancer detection from 4.5 to 5.3 cancers per 1,000 screens and raised biopsy rates compared with digital mammography, directly increasing downstream core needle biopsy volume in participating health systems.
Breast Cancer Core Needle Biopsy Market benefits from clinical preference for procedures that reduce patient burden while maintaining diagnostic accuracy. Core needle biopsy supports outpatient workflows and can be guided by imaging to improve lesion targeting. Providers increasingly use image-guided biopsy to minimize procedural complications and reduce repeat procedures. Breast Cancer Core Needle Biopsy Market expansion is reinforced by the need to obtain adequate tissue for histopathology and biomarker testing without surgical excision.
For instance, an audit of 467 patients undergoing breast needle core biopsy reported a false-negative rate of just 0.85% and a negative predictive value of 98.4% for BI-RADS 3 lesions, allowing many patients to avoid diagnostic surgery.
Workflow standardization and imaging-guided efficiency gains
Breast Cancer Core Needle Biopsy Market adoption is strengthened by workflow improvements that enable faster procedures and predictable outcomes. Facilities invest in standardized biopsy protocols and staff training to improve throughput and reduce variability. Real-time or high-precision guidance helps clinicians sample lesions effectively and improves confidence in negative or borderline findings. Breast Cancer Core Needle Biopsy Market growth is supported as diagnostic imaging centers and hospitals prioritize capacity optimization and consistent clinical quality.
Growth of specialized breast care delivery networks
Breast Cancer Core Needle Biopsy Market demand increases as specialty breast care clinics and coordinated referral networks expand access to imaging and biopsy services. Consolidated care pathways improve patient navigation from screening to biopsy and subsequent oncology consultation. Hospitals remain central, but diagnostic imaging centers increasingly contribute to procedure volume through accessible outpatient workflows. Breast Cancer Core Needle Biopsy Market expansion is supported by this broader distribution of care settings, which increases overall procedure availability.
Breast Cancer Core Needle Biopsy Market Challenges
Breast Cancer Core Needle Biopsy Market faces operational challenges linked to variability in lesion presentation and imaging visibility, which can increase procedure complexity and repeat sampling risk. Facilities with limited access to advanced guidance modalities may face constraints in handling MRI-only detected lesions or challenging calcifications. Staffing, training, and protocol adherence also influence consistency of outcomes across care sites. Breast Cancer Core Needle Biopsy Market performance can be affected when pathology turnaround time is slow or when coordination between imaging and pathology workflows is fragmented.
For instance, MRI‑guided vacuum biopsy with a handheld device achieved an accuracy of 98% (48/49 lesions) in one series, illustrating how access to such systems can enable reliable histologic verification of MRI‑only findings that would otherwise remain difficult to sample. Staffing, training, and protocol adherence also influence consistency of outcomes across care sites.
Breast Cancer Core Needle Biopsy Market cost and procurement constraints can influence adoption patterns across regions and care settings. Budget limitations may delay upgrades of imaging-guided biopsy systems or limit consumable standardization across multi-site providers. Differences in reimbursement structures can shape modality selection and procedure volume distribution across hospitals versus outpatient settings. Breast Cancer Core Needle Biopsy Market growth may also be moderated where patient access barriers delay diagnostic follow-up after screening abnormalities.
Breast Cancer Core Needle Biopsy Market Trends and Opportunities
Breast Cancer Core Needle Biopsy Market trends include greater integration of biopsy workflows with digital imaging, structured reporting, and coordinated care pathways that reduce diagnostic cycle time. Providers increasingly adopt approaches that improve patient experience through shorter procedures, efficient scheduling, and streamlined follow-up communication. Demand is also influenced by the need for reliable tissue acquisition to support biomarker-driven treatment decisions. Breast Cancer Core Needle Biopsy Market opportunity expands as facilities standardize protocols to improve throughput and reduce repeat procedures.
Breast Cancer Core Needle Biopsy Market opportunity is supported by expanding diagnostic infrastructure in emerging healthcare systems and by broader adoption of specialized breast care clinics. As imaging center networks scale, outpatient biopsy capacity increases, especially for ultrasound-guided procedures. Technology upgrades that improve targeting precision and workflow efficiency support equipment replacement cycles across hospitals and imaging centers. Breast Cancer Core Needle Biopsy Market growth potential is reinforced as awareness and screening participation improve across Asia Pacific and parts of Latin America.
For instance, multicenter evaluations of ultrasound‑guided large‑core biopsy in routine practice have shown sensitivity around 96.5% for invasive breast cancer with an average of 2.21 cores per lesion, making it feasible for newer breast units to deliver high‑quality diagnosis without immediate recourse to surgical excision.
Regional Insights
North America
Breast Cancer Core Needle Biopsy Market in North America held 45.80% share in 2025, reflecting mature screening programs and strong penetration of image-guided biopsy services. Hospitals and diagnostic imaging centers operate well-established pathways for rapid tissue confirmation and follow-up care coordination. Technology availability across guidance modalities supports management of diverse lesion types, including complex presentations. Demand is sustained by high diagnostic awareness and organized referral networks that translate screening findings into biopsy volumes.
Europe
Breast Cancer Core Needle Biopsy Market in Europe accounted for 21.30% share in 2025, supported by national screening initiatives and broad access to diagnostic imaging infrastructure. Many care systems emphasize minimally invasive diagnostics to reduce surgical burden and optimize resource use. Hospitals and imaging centers maintain structured care pathways that support consistent biopsy utilization for suspicious findings. Adoption is influenced by reimbursement frameworks and procurement discipline, which can shape equipment refresh timing and modality mix.
Asia Pacific
Breast Cancer Core Needle Biopsy Market in Asia Pacific represented 22.40% share in 2025, driven by expanding diagnostic capacity and rising awareness of early detection. Large urban centers and private hospital networks continue to scale imaging and biopsy services, increasing procedure accessibility. Demand growth is supported by improving screening participation and higher follow-up rates for suspicious imaging findings. Variability in healthcare access across countries remains, but expanding imaging-center networks support broader adoption of image-guided biopsy.
Latin America
Breast Cancer Core Needle Biopsy Market in Latin America reached 6.00% share in 2025, reflecting growth in diagnostic infrastructure alongside uneven access across healthcare systems. Procedure volumes are concentrated in larger metropolitan hospitals and private diagnostic networks. Increased awareness and screening participation support rising need for confirmatory tissue sampling, particularly where outpatient imaging services expand. Reimbursement variability and procurement constraints can influence the speed of technology upgrades and consistency of service availability.
Middle East & Africa
Breast Cancer Core Needle Biopsy Market in Middle East & Africa captured 4.50% share in 2025, supported by gradual expansion of advanced diagnostics in major urban centers. GCC markets and selected tertiary centers invest in imaging and biopsy capabilities, improving access to minimally invasive diagnosis. Demand growth is linked to rising awareness and improvements in referral pathways from screening to biopsy. Market development remains uneven across the region due to infrastructure gaps and differences in healthcare funding.
Competitive Landscape
Breast Cancer Core Needle Biopsy Market competition is shaped by product reliability, guidance compatibility, workflow efficiency, and the ability to support consistent tissue acquisition across diverse lesion types. Companies differentiate through integrated imaging-plus-biopsy ecosystems, consumable portfolios, and clinician-focused usability improvements that reduce procedure time and repeat sampling risk. Strategic focus areas include expanding installation base in hospitals and imaging networks, strengthening service support, and enabling standardized biopsy protocols across multi-site providers.
Hologic, Inc. maintains competitive positioning through breast health portfolio breadth that aligns imaging, biopsy workflow needs, and procedural efficiency expectations across screening-to-diagnosis pathways. Product strategy typically emphasizes system usability, consistent sample acquisition, and compatibility with imaging-guided procedures to support high-volume clinical environments. Commercial traction is supported by hospital and diagnostic network adoption patterns that prioritize streamlined workflows and predictable performance. Breast Cancer Core Needle Biopsy Market competition remains active as peers expand modality coverage and refine device ergonomics and consumable options.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
In February 2025, Hologic, Inc. announced that its Affirm Contrast Biopsy Software received the CE mark, enabling contrast-enhanced mammography–guided targeting and tissue acquisition on Selenia Dimensions and 3Dimensions mammography systems for breast biopsy procedures, strengthening its breast intervention portfolio in the breast cancer core needle biopsy space.
In January 2026, BD (Becton, Dickinson and Company) received FDA 510(k) clearance for the EnCor EnCompass breast biopsy and tissue removal system, a new multi‑modality breast biopsy platform designed to allow clinicians to perform minimally invasive breast biopsies across various imaging modalities using a single integrated system, with commercial launch planned for early 2026.
In March 2026, Mammotome, a Danaher company, secured FDA clearance for the Mammotome Prima MR Dual Vacuum‑Assisted Breast Biopsy System, the first MR‑guided breast biopsy solution designed to be positioned in the MRI scanner room at the patient’s side, along with the HydroMARK Plus Breast Biopsy Site Marker for MR, enhancing precision and workflow in MR‑guided breast biopsy procedures relevant to core needle biopsy applications.
Report Scope
Report Attribute
Details
Market size value in 2025
USD 923.45 million
Revenue forecast in 2032
USD 1256.69 million
Growth rate (CAGR)
4.5% (2025–2032)
Base year
2025
Forecast period
2026-2032
Quantitative units
USD million
Segments covered
By Technology Outlook: MRI-based Breast Biopsy, Ultrasound-based Breast Biopsy, Mammography-based Breast Biopsy, CT-based Breast Biopsy, Other Image-Based Breast Biopsy; By Application Outlook: Breast lesion diagnosis, Breast cancer confirmation, Calcification sampling, Histopathology / tissue characterization; By End User Outlook: Hospitals, Diagnostic imaging centers, Ambulatory surgical centers, Specialty breast care clinics, Research and academic institutes
Regional scope
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Key companies profiled
Hologic, Inc.; BD (Becton, Dickinson and Company); Mammotome; Danaher Corporation; Argon Medical Devices; Merit Medical Systems; Cook Medical; GE HealthCare; Siemens Healthineers; FUJIFILM Healthcare; Planmed Oy; STERYLAB; QIAGEN; Biocept, Inc.
No. of Pages
327
Segmentation
By Technology
MRI-based Breast Biopsy
Ultrasound-based Breast Biopsy
Mammography-based Breast Biopsy
CT-based Breast Biopsy
Other Image-Based Breast Biopsy
By Application
Breast lesion diagnosis
Breast cancer confirmation
Calcification sampling
Histopathology / tissue characterization
By End User
Hospitals
Diagnostic imaging centers
Ambulatory surgical centers
Specialty breast care clinics
Research and academic institutes
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
South-east Asia
Rest of Asia Pacific
Latin America
Brazil
Argentina
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of the Middle East and Africa
1. Introduction
1.1. Report Description
1.2. Purpose of the Report
1.3. USP & Key Offerings
1.4. Key Benefits for Stakeholders
1.5. Target Audience
1.6. Report Scope
1.7. Regional Scope 2. Scope and Methodology
2.1. Objectives of the Study
2.2. Stakeholders
2.3. Data Sources
2.3.1. Primary Sources
2.3.2. Secondary Sources
2.4. Market Estimation
2.4.1. Bottom-Up Approach
2.4.2. Top-Down Approach
2.5. Forecasting Methodology 3. Executive Summary 4. Introduction
4.1. Overview
4.2. Key Industry Trends 5. Global Breast Cancer Core Needle Biopsy Market
5.1. Market Overview
5.2. Market Performance
5.3. Impact of COVID-19
5.4. Market Forecast 6. Market Breakup by Technology
6.1. MRI-based Breast Biopsy
6.1.1. Market Trends
6.1.2. Market Forecast
6.1.3. Revenue Share
6.1.4. Revenue Growth Opportunity
6.2. Ultrasound-based Breast Biopsy
6.2.1. Market Trends
6.2.2. Market Forecast
6.2.3. Revenue Share
6.2.4. Revenue Growth Opportunity
6.3. Mammography-based Breast Biopsy
6.3.1. Market Trends
6.3.2. Market Forecast
6.3.3. Revenue Share
6.3.4. Revenue Growth Opportunity
6.4. CT-based Breast Biopsy
6.4.1. Market Trends
6.4.2. Market Forecast
6.4.3. Revenue Share
6.4.4. Revenue Growth Opportunity
6.5. Other Image-Based Breast Biopsy
6.5.1. Market Trends
6.5.2. Market Forecast
6.5.3. Revenue Share
6.5.4. Revenue Growth Opportunity 7. Market Breakup by Application
7.1. Breast lesion diagnosis
7.1.1. Market Trends
7.1.2. Market Forecast
7.1.3. Revenue Share
7.1.4. Revenue Growth Opportunity
7.2. Breast cancer confirmation
7.2.1. Market Trends
7.2.2. Market Forecast
7.2.3. Revenue Share
7.2.4. Revenue Growth Opportunity
7.3. Calcification sampling
7.3.1. Market Trends
7.3.2. Market Forecast
7.3.3. Revenue Share
7.3.4. Revenue Growth Opportunity
7.4. Histopathology / tissue characterization
7.4.1. Market Trends
7.4.2. Market Forecast
7.4.3. Revenue Share
7.4.4. Revenue Growth Opportunity 8. Market Breakup by End User
8.1. Hospitals
8.1.1. Market Trends
8.1.2. Market Forecast
8.1.3. Revenue Share
8.1.4. Revenue Growth Opportunity
8.2. Diagnostic imaging centers
8.2.1. Market Trends
8.2.2. Market Forecast
8.2.3. Revenue Share
8.2.4. Revenue Growth Opportunity
8.3. Ambulatory surgical centers
8.3.1. Market Trends
8.3.2. Market Forecast
8.3.3. Revenue Share
8.3.4. Revenue Growth Opportunity
8.4. Specialty breast care clinics
8.4.1. Market Trends
8.4.2. Market Forecast
8.4.3. Revenue Share
8.4.4. Revenue Growth Opportunity
8.5. Research and academic institutes
8.5.1. Market Trends
8.5.2. Market Forecast
8.5.3. Revenue Share
8.5.4. Revenue Growth Opportunity 9. Market Breakup by Region
9.1. North America
9.1.1. United States
9.1.1.1. Market Trends
9.1.1.2. Market Forecast
9.1.2. Canada
9.1.2.1. Market Trends
9.1.2.2. Market Forecast
9.1.3. Mexico
9.1.3.1. Market Trends
9.1.3.2. Market Forecast
9.2. Europe
9.2.1. Germany
9.2.2. France
9.2.3. United Kingdom
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia-Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Rest of Asia-Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Argentina
9.4.3. Rest of Latin America
9.5. Middle East and Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa 10. SWOT Analysis
10.1. Overview
10.2. Strengths
10.3. Weaknesses
10.4. Opportunities
10.5. Threats 11. Value Chain Analysis 12. Porters Five Forces Analysis
12.1. Overview
12.2. Bargaining Power of Buyers
12.3. Bargaining Power of Suppliers
12.4. Degree of Competition
12.5. Threat of New Entrants
12.6. Threat of Substitutes 13. Price Analysis 14. Competitive Landscape
14.1. Market Structure
14.2. Key Players
14.3. Profiles of Key Players
14.3.1. Hologic, Inc.
14.3.1.1. Company Overview
14.3.1.2. Product Portfolio
14.3.1.3. Financials
14.3.1.4. SWOT Analysis
14.3.2. BD (Becton, Dickinson and Company)
14.3.3. Mammotome
14.3.4. Danaher Corporation
14.3.5. Argon Medical Devices
14.3.6. Merit Medical Systems
14.3.7. Cook Medical
14.3.8. GE HealthCare
14.3.9. Siemens Healthineers
14.3.10. FUJIFILM Healthcare
14.3.11. Planmed Oy
14.3.12. STERYLAB
14.3.13. QIAGEN
14.3.14. Biocept, Inc. 15. Research Methodology
Request A Free Sample
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions:
What is the market size of the Breast Cancer Core Needle Biopsy Market in 2025?
Breast Cancer Core Needle Biopsy Market size was USD 923.45 million in 2025. The market value reflects global demand for image-guided, minimally invasive tissue sampling.
What will be the market size by 2032?
Breast Cancer Core Needle Biopsy Market is expected to reach USD 1,256.69 million by 2032. Growth is linked to screening follow-up needs and diagnostic pathway expansion.
What is the CAGR for 2025–2032?
Breast Cancer Core Needle Biopsy Market is projected to grow at a 4.5% CAGR during 2025–2032. The growth rate reflects steady expansion in biopsy procedure volumes.
Which is the largest technology segment in 2025?
Ultrasound-based Breast Biopsy led with a 42.3% share in 2025. The segment leads due to real-time guidance and broad availability across imaging centers.
Who are the major players in the Breast Cancer Core Needle Biopsy Market?
Major players include Hologic, Inc., BD (Becton, Dickinson and Company), Mammotome, Danaher Corporation, and GE HealthCare. The competitive landscape also includes Siemens Healthineers, FUJIFILM Healthcare, and other listed companies.
Which region leads the Breast Cancer Core Needle Biopsy Market in 2025?
North America led with a 45.80% share in 2025. Regional leadership is supported by screening penetration and strong diagnostic infrastructure.
About Author
Shweta Bisht
Healthcare & Biotech Analyst
Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.
The global Blood Platelets Market size was estimated at USD 6154.6 million in 2025 and is expected to reach USD 8044.68 million by 2032, growing at a CAGR of 3.9% from 2025 to 2032.
The global Bovine Tuberculosis Diagnosis Market size was estimated at USD 814.6 million in 2025 and is expected to reach USD 1086.47 million by 2032, growing at a CAGR of 4.2% from 2025 to 2032.
The global Bladder Cancer Therapeutics & Diagnostics Market size was estimated at USD 5690.23 million in 2025 and is expected to reach USD 8399.05 million by 2032, growing at a CAGR of 5.72% from 2025 to 2032.
The global Biotechnology Reagents Market size was estimated at USD 93,978.03 million in 2025 and is expected to reach USD 184,305.19 million by 2032, growing at a CAGR of 10.1% from 2025 to 2032.
The global Biohazard Bags Market size was estimated at USD 507.64 million in 2025 and is expected to reach USD 763.3 million by 2032, growing at a CAGR of 6% from 2025 to 2032.
The global Biguanides Market size was estimated at USD 18.64 million in 2025 and is expected to reach USD 23.88 million by 2032, growing at a CAGR of 3.6% from 2025 to 2032.
The global Biobetters Market size was estimated at USD 71522.2 million in 2025 and is expected to reach USD 123933.49 million by 2032, growing at a CAGR of 8.17% from 2025 to 2032.
The global Behavioral & Mental Health Software Market size was estimated at USD 7,477.6 million in 2025 and is expected to reach USD 22,148.34 million by 2032, growing at a CAGR of 16.78% from 2025 to 2032.
The global Axial Spondyloarthritis Market size was estimated at USD 6,707.16 million in 2025 and is expected to reach USD 9,066.55 million by 2032, growing at a CAGR of 4.4% from 2025 to 2032.
The Alopecia Treatment / Hair Loss Market is projected to grow from USD 3657.5 million in 2025 to an estimated USD 5257.27 million by 2032, with a compound annual growth rate (CAGR) of 5.3% from 2025 to 2032.
The Alzheimer’s Diagnosis and Drugs Market is projected to grow from USD 8,136.6 million in 2025 to an estimated USD 11,487.23 million by 2032, with a compound annual growth rate (CAGR) of 5.1% from 2025 to 2032.
Licence Option
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$4999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$5999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
